MedTrace Logo

Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension

NCT00551408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2018-10-16

No results posted yet for this study

Summary

Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair.

Current evidence established that endothelial progenitor cells (EPC) participate in several models of vascular disease as acute coronary syndromes, stroke, diabetes, peripheral artery disease, etc. However EPC in the setting of PAH is less well established. The target of this study is to demonstrate if the number of EPC is increased in a mexican population of patients with PAH.

Conditions

  • Pulmonary Idiopathic Arterial Hypertension

Sponsors & Collaborators

  • Unidad de Investigacion Clinica en Medicina S.C.

    lead NETWORK

Principal Investigators

  • Carlos J Sanchez Diaz, MD. · Unidad de Investigacion Clinica en Medicina SC.

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-07-31
Completion
2016-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551408 on ClinicalTrials.gov